Limits...
A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs.

Hori K, Saito S, Kubota K - Br. J. Cancer (2002)

Bottom Line: The change in tumour blood flow and the therapeutic effect of AC7700 on microtumours were observed directly by using Sato lung carcinoma implanted in a rat transparent chamber.In every tumour, tumour blood flow began to decrease immediately after AC7700 administration and reached a minimum at approximately 30 min after injection.These results demonstrate that AC7700 is effective for tumours growing in various tissues and organs and for metastases.

View Article: PubMed Central - PubMed

Affiliation: Department of Vascular Biology, Division of Cancer Control, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryomachi, Aoba-ku, Sendai 980-8575, Japan. k-hori@idac.tohoku.ac.jp

Show MeSH

Related in: MedlinePlus

Inhibition of SLC tumour growth caused by AC7700 in the tumour developing in a transparent chamber. Tumour size at the start of observation was defined as 100%. During the 48 h after a single i.v. administration of 10 mg kg−1 AC7700, tumour size did not change at all (solid circle) (n=4). In contrast, tumours in the control group continued to grow (open circle) (n=4). Tumour area doubling time was 41.7±11.4 h.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2746587&req=5

fig7: Inhibition of SLC tumour growth caused by AC7700 in the tumour developing in a transparent chamber. Tumour size at the start of observation was defined as 100%. During the 48 h after a single i.v. administration of 10 mg kg−1 AC7700, tumour size did not change at all (solid circle) (n=4). In contrast, tumours in the control group continued to grow (open circle) (n=4). Tumour area doubling time was 41.7±11.4 h.

Mentions: Figure 7Figure 7


A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs.

Hori K, Saito S, Kubota K - Br. J. Cancer (2002)

Inhibition of SLC tumour growth caused by AC7700 in the tumour developing in a transparent chamber. Tumour size at the start of observation was defined as 100%. During the 48 h after a single i.v. administration of 10 mg kg−1 AC7700, tumour size did not change at all (solid circle) (n=4). In contrast, tumours in the control group continued to grow (open circle) (n=4). Tumour area doubling time was 41.7±11.4 h.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2746587&req=5

fig7: Inhibition of SLC tumour growth caused by AC7700 in the tumour developing in a transparent chamber. Tumour size at the start of observation was defined as 100%. During the 48 h after a single i.v. administration of 10 mg kg−1 AC7700, tumour size did not change at all (solid circle) (n=4). In contrast, tumours in the control group continued to grow (open circle) (n=4). Tumour area doubling time was 41.7±11.4 h.
Mentions: Figure 7Figure 7

Bottom Line: The change in tumour blood flow and the therapeutic effect of AC7700 on microtumours were observed directly by using Sato lung carcinoma implanted in a rat transparent chamber.In every tumour, tumour blood flow began to decrease immediately after AC7700 administration and reached a minimum at approximately 30 min after injection.These results demonstrate that AC7700 is effective for tumours growing in various tissues and organs and for metastases.

View Article: PubMed Central - PubMed

Affiliation: Department of Vascular Biology, Division of Cancer Control, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryomachi, Aoba-ku, Sendai 980-8575, Japan. k-hori@idac.tohoku.ac.jp

Show MeSH
Related in: MedlinePlus